Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A injection for early postoperative cognitive function in neurosurgical patients under general anesthesia
ChiCTR2100050023Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Aug 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Huperzine A in perioperative neurocognitive disorder (2 arms), sponsored by Xinhua Hospital. Primary endpoint: Mini-mental State Examination (MMSE). Started Aug 2021; status: recruiting.
02
Drugs
Huperzine A
03
Conditions
perioperative neurocognitive disorder
Beyond the preview
Go deeper on ChiCTR2100050023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050023.